Identification of COPD Inflammatory Endotypes Using Repeated Sputum Eosinophil Counts

Beech, Augusta; Jackson, Natalie; Singh, Dave

doi:10.3390/biomedicines10102611

Cited by 6 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Almost one third of our subjects (28.3%) showed high sputum eosinophils at baseline without any changes during the follow-up. Stability of low (< 1%) and intermediate (1-3%) sputum eosinophils was recently demonstrated in a 6-month monitoring study of COPD patients [21]. We found a poor correlation between blood and sputum eosinophils at baseline, in agreement with our previous study [2].…”

Section: Discussionsupporting

confidence: 92%

Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up

Pignatti,

Visca,

Zappa

et al. 2024

Preprint

View full text Add to dashboard Cite

Background High blood eosinophils seem to predict exacerbations and response to inhaled corticosteroids (ICS) treatment in patients with chronic obstructive pulmonary disease (COPD). The aim of our study was to prospectively evaluate for 2 years, blood and sputum eosinophils in COPD patients treated with bronchodilators only at recruitment. Methods COPD patients in stable condition treated with bronchodilators only underwent monitoring of lung function, blood and sputum eosinophils, exacerbations and comorbidities every 6 months for 2 years. ICS was added during follow-up when symptoms worsened. Results 63 COPD patients were enrolled: 53 were followed for 1 year, 41 for 2 years, 10 dropped-out. After 2 years, ICS was added in 12/41 patients (29%) without any statistically significant difference at time points considered. Blood and sputum eosinophils did not change during follow-up. Only FEV1/FVC at T0 was predictive of ICS addition during the 2 year-follow-up (OR:0.91; 95% CI: 0.83–0.99, p = 0.03). ICS addition did not impact on delta (T24-T0) FEV1, blood and sputum eosinophils and exacerbations. After 2 years, patients who received ICS had higher blood eosinophils than those in bronchodilator therapy (p = 0.042). Patients with history of ischemic heart disease increased blood eosinophils after 2 years [p = 0.03 for both percentage and counts]. Conclusions Almost 30% of mild/moderate COPD patients in bronchodilator therapy received ICS for worsened symptoms in a 2 year-follow-up. Only FEV1/FVC at T0 seems to predict ICS addition during follow-up. Blood and sputum eosinophils were not associated with worsened symptoms or exacerbations. History of ischemic heart disease seems to be associated with a progressive increase of blood eosinophils.

show abstract

Section: Discussionsupporting

confidence: 92%

Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up

Pignatti,

Visca,

Zappa

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that lower eosinophil counts confer the greatest temporal stability, using blood [ 17 , 18 ] and tissue [ 19 ]. A study of 100 COPD patients reported consistent results concerning sputum eosinophil counts [ 20 , 21 ]. The authors found that lower levels of sputum eosinophils (<1%) were stable over 6 months whereas those with higher eosinophil counts (≥1%) were more temporally variable.…”

Section: Copdmentioning

confidence: 60%

ERS International Congress 2022: highlights from the Airway Diseases Assembly

et al. 2023

Self Cite

View full text Add to dashboard Cite

The European Respiratory Society (ERS) celebrated the return of an in-person meeting in Barcelona, Spain, after two years of virtual congresses. The congress programme was replete with symposia, skills workshops and abstract presentations from all 14 assemblies, encompassing over 3000 abstracts presented in the form of thematic poster discussion and oral presentations. In this article, highlights from this year's congress (including that from thematic poster sessions, oral presentations and symposia from keynote speakers), presented by Assembly 5: Airway diseases, Asthma, COPD and Chronic Cough, are reviewed by Early Career Members and experts in the field, with the aim of presenting key recent findings in the field.

show abstract

“…However, more data are needed to confirm this trend. Stability of low (< 1%) and intermediate (1–3%) sputum eosinophils was recently demonstrated in a 6-month monitoring study of COPD patients [ 21 ]. We found a poor correlation between blood and sputum eosinophils at baseline, in agreement with our previous study [ 2 ].…”

Section: Discussionmentioning

confidence: 99%

Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up

Pignatti,

Visca,

Zappa

et al. 2024

BMC Pulm Med

View full text Add to dashboard Cite

Background High blood eosinophils seem to predict exacerbations and response to inhaled corticosteroids (ICS) treatment in patients with chronic obstructive pulmonary disease (COPD). The aim of our study was to prospectively evaluate for 2 years, blood and sputum eosinophils in COPD patients treated with bronchodilators only at recruitment. Methods COPD patients in stable condition treated with bronchodilators only underwent monitoring of lung function, blood and sputum eosinophils, exacerbations and comorbidities every 6 months for 2 years. ICS was added during follow-up when symptoms worsened. Results 63 COPD patients were enrolled: 53 were followed for 1 year, 41 for 2 years, 10 dropped-out. After 2 years, ICS was added in 12/41 patients (29%) without any statistically significant difference at time points considered. Blood and sputum eosinophils did not change during follow-up. Only FEV1/FVC at T0 was predictive of ICS addition during the 2 year-follow-up (OR:0.91; 95% CI: 0.83–0.99, p = 0.03). ICS addition did not impact on delta (T24-T0) FEV1, blood and sputum eosinophils and exacerbations. After 2 years, patients who received ICS had higher blood eosinophils than those in bronchodilator therapy (p = 0.042). Patients with history of ischemic heart disease increased blood eosinophils after 2 years [p = 0.03 for both percentage and counts]. Conclusions Blood and sputum eosinophils remained stable during the 2 year follow-up and were not associated with worsened symptoms or exacerbations. Almost 30% of mild/moderate COPD patients in bronchodilator therapy at enrollment, received ICS for worsened symptoms in a 2 year-follow-up and only FEV1/FVC at T0 seems to predict this addition. History of ischemic heart disease seems to be associated with a progressive increase of blood eosinophils.

show abstract

Identification of COPD Inflammatory Endotypes Using Repeated Sputum Eosinophil Counts

Cited by 6 publications

References 41 publications

Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up

Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up

ERS International Congress 2022: highlights from the Airway Diseases Assembly

Monitoring COPD patients: systemic and bronchial eosinophilic inflammation in a 2-year follow-up

Contact Info

Product

Resources

About